4.72
前日終値:
$4.70
開ける:
$4.59
24時間の取引高:
70,550
Relative Volume:
0.29
時価総額:
$3.21M
収益:
$12.99M
当期純損益:
$-23.72M
株価収益率:
-0.0485
EPS:
-97.2514
ネットキャッシュフロー:
$-23.28M
1週間 パフォーマンス:
-14.31%
1か月 パフォーマンス:
-58.30%
6か月 パフォーマンス:
-97.72%
1年 パフォーマンス:
-99.12%
Aptevo Therapeutics Inc Stock (APVO) Company Profile
APVO を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
APVO
Aptevo Therapeutics Inc
|
4.72 | 185.90K | 12.99M | -23.72M | -23.28M | -97.25 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2018-11-05 | 開始されました | Ladenburg Thalmann | Buy |
2017-10-05 | 再開されました | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc (APVO) 最新ニュース
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Decrease in Short Interest - Defense World
Aptevo Therapeutics (APVO) Trading Suspended as News Awaits | AP - GuruFocus
Aptevo Therapeutics (APVO) Trading Suspended as News Awaits | APVO Stock News - GuruFocus
Aptevo Therapeutics Approves 1-for-20 Reverse Stock Split - TipRanks
Aptevo Therapeutics Announces Reverse Stock Split - TipRanks
Aptevo Therapeutics to Implement 1-for-20 Reverse Stock Split - marketscreener.com
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as pa - GuruFocus
Aptevo Therapeutics (APVO) Announces 1-for-20 Reverse Stock Split | APVO Stock News - GuruFocus
Aptevo Therapeutics enacts reverse stock split to maintain Nasdaq compliance - Investing.com
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan - ACCESS Newswire
Aptevo's Dramatic 1:20 Reverse Split Cuts Shares from 13.5M to 0.7M in Nasdaq Compliance Push - Stock Titan
StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO) - Defense World
Aptevo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aptevo reports high remission in AML patients with new drug By Investing.com - Investing.com South Africa
APVO: Promising Trial Results Propel AML Treatment Innovations | - GuruFocus
APVO: Promising Trial Results Propel AML Treatment Innovations | APVO Stock News - GuruFocus
Aptevo reports high remission in AML patients with new drug - Investing.com Australia
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig | APVO Stock News - GuruFocus
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig - ACCESS Newswire
Breakthrough: New AML Drug Shows 90% Remission Rate With Zero Cytokine Release Syndrome - Stock Titan
Aptevo Therapeutics (APVO) Expected to Announce Earnings on Wednesday - Defense World
Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com - Defense World
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - ACCESS Newswire
Aptevo Therapeutics Provides Program Update for Bispecific APVO7 - GuruFocus
Aptevo Therapeutics Says In Preclinical Studies APVO711 Demonstrates Dual Anti-Cancer Functionality - marketscreener.com
Aptevo Therapeutics (APVO) Advances Innovative Immunotherapy wit - GuruFocus
Aptevo Therapeutics (APVO) Advances Innovative Immunotherapy with APVO711 Update | APVO Stock News - GuruFocus
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation | APVO Stock News - GuruFocus
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation - ACCESS Newswire
Aptevo Therapeutics announces common stock offering - Investing.com Australia
APVO’s latest rating updates from top analysts. - knoxdaily.com
Strategic Moves Drive Stock Gains For OSR, Lianhe Sowell, And Aptevo - Finimize
Aptevo Therapeutics announces common stock offering By Investing.com - Investing.com Canada
Closing Bell Recap: Aptevo Therapeutics Inc (APVO) Ends at 0.61, Reflecting a -9.31 Downturn - DWinneX
Aptevo Therapeutics announces at-the-market offering - Investing.com Australia
APVO stock plunges to 52-week low, touches $0.59 - Investing.com
APVO stock plunges to 52-week low, touches $0.59 By Investing.com - Investing.com UK
Aptevo Therapeutics announces at-the-market offering By Investing.com - Investing.com India
SEC Form 424B4 filed by Aptevo Therapeutics Inc. - Quantisnow
Press Release Distribution & PR Platform - ACCESS Newswire
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering - ACCESS Newswire
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - ACCESS Newswire
Applied Materials Q2 Earnings: Tech Giant's Financial Results Coming May 15 - Stock Titan
A look into Aptevo Therapeutics Inc (APVO)’s deeper side - Sete News
Aptevo Therapeutics Inc’s latest rating changes from various analysts - knoxdaily.com
Evogene (EVGN) Sees Dramatic Surge in Investor Interest Amid Strategic Moves | APVO Stock News - GuruFocus
Market Momentum: Aptevo Therapeutics Inc (APVO) Registers a 9.08 Increase, Closing at 0.69 - DWinneX
Aptevo Therapeutics Inc (APVO) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):